Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea flag South Korea · Delayed Price · Currency is KRW
46,800
+800 (1.74%)
Apr 8, 2026, 3:30 PM KST

Hanall Biopharma Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,335,9192,221,6191,959,9522,245,705902,2901,077,892
Market Cap Growth
32.99%13.35%-12.72%148.89%-16.29%-43.84%
Enterprise Value
2,343,0932,211,0371,934,1972,185,410836,710991,822
Last Close Price
46000.0043750.0038650.0044300.0017800.0021050.00
PE Ratio
---640.063588.03121.16
Forward PE
943.81-117.15261.09112.3065.12
PS Ratio
15.0514.3214.1116.658.2010.61
PB Ratio
14.4513.7411.6412.065.366.59
P/TBV Ratio
14.8614.1311.9612.185.436.68
P/FCF Ratio
--253.9382.4740.22-
P/OCF Ratio
--209.4075.7635.711283.40
PEG Ratio
-19.0919.0919.0919.0919.09
EV/Sales Ratio
15.1014.2513.9216.207.619.76
EV/EBITDA Ratio
-1134.12577.20437.93183.5577.34
EV/EBIT Ratio
--8392.221253.51555.6698.21
EV/FCF Ratio
-712.54-250.6080.2637.30-
Debt / Equity Ratio
0.200.200.010.010.010.01
Debt / EBITDA Ratio
16.3716.370.430.260.290.10
Debt / FCF Ratio
--0.190.050.06-
Net Debt / Equity Ratio
0.040.04-0.14-0.30-0.31-0.48
Net Debt / EBITDA Ratio
3.683.68-6.94-11.06-11.54-6.18
Net Debt / FCF Ratio
-2.18-2.18-3.01-2.03-2.3521.04
Asset Turnover
0.710.710.610.600.530.49
Inventory Turnover
1.961.961.882.082.112.05
Quick Ratio
0.990.991.292.102.974.35
Current Ratio
1.911.912.463.023.925.37
Return on Equity (ROE)
-3.37%-3.37%-1.02%1.98%0.15%5.16%
Return on Assets (ROA)
-0.46%-0.46%0.06%0.48%0.46%3.02%
Return on Invested Capital (ROIC)
-1.02%-1.03%0.17%1.41%0.20%11.52%
Return on Capital Employed (ROCE)
-0.90%-0.90%0.10%0.90%0.80%5.70%
Earnings Yield
-0.24%-0.25%-0.09%0.16%0.03%0.83%
FCF Yield
-0.14%-0.15%0.39%1.21%2.49%-0.35%
Buyback Yield / Dilution
-0.13%-0.13%-0.04%0.24%0.76%-0.05%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.